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ties were included as covariates. RESULTS: Following discharge
from initial hospitalization, the mean cost was $3755.28, the
mean number of outpatient visits was 4.14, and the mean
number of hospitalizations was 0.11 per two-month period, for
patients with post-MI HF. If these patients had not developed
HF, the estimated savings per 2-month interval was $1716, and
the estimated reduction in the number of visits and hospitaliza-
tions per 2-month interval was 30% and 50% respectively.
CONCLUSIONS: The development of HF in post-MI patients
results in a signiﬁcant increase in costs, outpatient visits and hos-
pitalizations as compared to post-MI patients without HF. The
cost of newer drugs that aim to delay or prevent the onset of
post-MI HF may be offset by savings in costs and resource uti-
lization attributable to HF in post-MI patients.
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OBJECTIVES: The Losartan Intervention for End Point Reduc-
tion in Hypertension (LIFE) study demonstrated a 13% relative
risk reduction in the primary composite endpoint (myocardial
infarction, stroke or death) and a 25% relative risk reduction in
stroke for patients treated with losartan compared to patients
treated with a ﬁrst-line antihypertensive agent (atenolol). Incor-
porating the results found in the LIFE study, an incremental cost-
effectiveness analysis was performed to determine the economic
feasibility of making losartan a ﬁrst line anti-hypertensive agent
in the prevention of cardiovascular morbidity and mortality.
METHODS: A Markov State Transition model was developed
to extrapolate the outcomes observed during the 4-year LIFE
trial to the patients’ lifetime. A comprehensive model was created
by drawing information from a number of sources within the 
literature, including other longitudinal cohort studies on patients
in the deﬁned health states. Considering a societal perspective,
fully allocated costs were calculated using the St. Paul’s Hospi-
tal Cost Model. QALY estimates for each of the given health
states were obtained from a variety of sources within the litera-
ture. Along with several univariate sensitivity analyses, extensive
probabilistic sensitivity analysis was performed in order to
examine the impact of a broad range of variation in our model
parameters. RESULTS: The incremental cost effectiveness ratio
of losartan versus atenolol was CDN$1337 (CDN$1 = US$0.78)
per QALY gained. This cost-effectiveness ratio was robust to
extensive sensitivity analysis, demonstrating a 95% probability
that the cost-effectiveness ratio would be less than CDN$20,000
per QALY gained. CONCLUSIONS: Losartan appears to be an
exciting, cost-effective alternative to traditional ﬁrst-line thera-
pies for hypertension. Results were robust to univariate and
probabilistic sensitivity analysis and are well within the accepted
ranges of cost-effectiveness ratios deemed to be efﬁcient and cost
effective.
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OBJECTIVE: To determine the cost-effectiveness of rosuvastatin
compared to ﬁve other statins, from a managed care payer per-
spective. METHODS: A decision-analytic model compared the
1-year costs and effectiveness of the following six statins, titrated
over the speciﬁed dose ranges in patients with elevated low-
density lipoprotein cholesterol (LDL): atorvastatin 10–80mg,
ﬂuvastatin 40–80mg, generic lovastatin 20–80mg, pravastatin
20–40mg, rosuvastatin 10–40mg, and simvastatin 20–80mg.
Effectiveness measures included percent change in LDL, high-
density lipoprotein cholesterol (HDL), and number of patients
achieving National Cholesterol Education Program (NCEP)
Second Adult Treatment Panel goal (per 10,000 treated). Effec-
tiveness estimates came from two 52-week, comparative clinical
trials and dose equivalence tables. Drug, physician and labora-
tory resource use were estimated using current NCEP guidelines,
then multiplied by Medicare reimbursement rates for services,
and wholesale acquisition costs for drugs. Probabilistic sensitiv-
ity analyses employed the net health beneﬁts framework 
and cost-effectiveness acceptability curves were constructed.
RESULTS: In the base-case analysis, rosuvastatin dominated
atorvastatin, lovastatin, pravastatin and simvastatin. Fluvastatin
was least costly but also least effective; rosuvastatin was most
effective and had the second lowest cost. Compared with ﬂu-
vastatin, the incremental LDL-C reduction, HDL-C increase, and
percent of patients to goal with rosuvastatin were 16%, 3%, and
27%, respectively. Incremental costs per additional 1% reduc-
tion in LDL-C, a 1% increase in HDL-C, and patient to goal
were $6, $33, and $353, respectively. Results were robust to
probabilistic analyses: in each of 1000 simulated populations of
1000 patients, rosuvastatin conferred more net health beneﬁts
than atorvastatin, lovastatin, pravastatin, or simvastatin. Rosu-
vastatin was the optimal choice among all statins when willing-
ness to pay for an additional 1% decrease in LDL, 1% increase
in HDL, and patient to goal exceeded $6, $37, and $353, respec-
tively. CONCLUSIONS: Rosuvastatin is less costly and more
effective than atorvastatin, lovastatin, pravastatin and simvas-
tatin; and highly cost-effective compared with ﬂuvastatin.
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OBJECTIVE: Coronary heart disease (CHD) is among the
leading causes of premature death in women. Cholesterol low-
ering therapies are beneﬁcial in primary and secondary preven-
tion of CHD. This study calculates the cost and efﬁcacy of
treating women with various HMGCoA reductase inhibitors
(statins). METHODS: Our analysis uses data from the Atorvas-
tatin Comparative Cholesterol Efﬁcacy and Safety Study
(ACCESS), a randomized, active-controlled, clinical trial. In
January 1999, 3273 patients completed the trial which had
assigned them to one of ﬁve study medications: atorvastatin
10–80mg/day; ﬂuvastatin 20–80mg/day; lovastatin 20–40
mg/day; pravastatin 20–40mg/day: or simvastatin 10–40mg/day.
We examined both costs of treatment to NCEP targets and 
efﬁcacy in achieving targets for men and women. Cost analyses
employed ordinary least squares regression and efﬁcacy analyses
employed logistic regression. RESULTS: In this study, we found
women to be $47 less costly to treat with lipid-lowering thera-
pies than men (95% CI: $US10-84), controlling for medication,
age, weight, race, blood pressure, baseline cholesterol level,
number of risk factors, diabetes, hypertension, and smoking
status. We found no difference in the likelihood of achieving
NCEP targets (odds ratio 0.984, 95% CI: 0.776–1.248), con-
trolling for the same factors as in the cost analysis. CONCLU-
